Erratum: Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection (FEMS Immunology and Medical Microbiology (2004) 42 (241-248) DOI: 10.1016/j.femsim.2004.05.008);Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection

FEMS Immunology and Medical Microbiology

Volumn 42, Issue 2, 2004, Pages 241-248

  Tewary, Poonam ^a   Mehta, Jayesh ^a   Sukumaran, Bindu ^a   Madhubala, Rentala ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

CpG oligodeoxynucleotides; L. donovani, vaccine; Soluble antigen

Indexed keywords

ANTIGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; LEISHMANIA VACCINE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PARASITE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; IMMUNITY; IMMUNIZATION; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PARASITE; PARASITOSIS; PRIORITY JOURNAL; PROMASTIGOTE; TH1 CELL; TH2 CELL; VACCINATION; VISCERAL LEISHMANIASIS;

EID: 4444228401     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.femsim.2004.10.002     Document Type: Erratum

References (43)

1. Baily G.G., Nandy A. Visceral leishmaniasis: more prevalent and more problematic. J. Infect. 29:1994;241-247
2. Herwaldt B.L. Leishmaniasis. Lancet. 354:1999;1191-1199
3. World Health Report. Thirteenth Programme Report (1997) Special Programme for Research and Training in Tropical Diseases. Leishmaniasis. World Health Organizations Publications, Geneva
4. Advances in battle against leishmaniasis. (1998) TDR News. 57, 2
5. Alexander J. A radioattenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana. Trans. R. Soc. Trop. Med. Hyg. 76:1982;646-649
6. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Seiky Y.A., Reed S.G., Grimaldi G. Jr. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun. 69:2001;4103-4108
7. Howard J.G., Nicklin S., Hale C., Liew F.Y. Prophylactic immunization against experimental leishmaniasis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J. Immunol. 129:1982;2206-2212
8. Howard J.G., Liew F.Y., Hale C., Nicklin S. Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes. J. Immunol. 132:1984;450-455
9. Mayrink W., da Costa C.A., Magalhaes P.A., Melo M.N., Dias M., Lima A.O., Michalick M.S., Williams P. A field trial of a vaccine against American dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 73:1979;385-387
10. Mayrink W., Antunes C.M., da Costa C.A., Melo M.N., Dias M., Michalick M.S., Magalhaes P.A., De Oliveira Lima A., Williams P. Further trials of a vaccine against American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 80:1986;1001
11. Handman E. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14:2001;229-243
12. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., Seder R.A. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1997;1137-1147
13. Sukumaran B., Tewary P., Saxena S., Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine. 21:2003;1292-1299
14. Sjolander A., Baldwin T.M., Curtis J.M., Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160:1998;3949-3957
15. Cabrera M., Blackwell J.M., Castes M., Trujillo D., Convit J., Shaw M.A. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol. 22:2000;73-79
16. Julia V., Rassoulzadegan M., Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science. 274:1996;421-423
17. 4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity. 6:1997;541-549
18. Diego Miralles G., Stoeckle M.Y., McDermott D.F., Finelman F.D., Murray H.W. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 62:1994;1058-1063
19. Kemp M., Kurtzhal J.A., Bendtzen K., Poulsen L.K., Hansen M.B., Koech D.K., Kharazmi A., Theander T.G. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect. Immun. 61:1993;1069-1073
20. Kaye P.M., Curry A.J., Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:1991;2763-2770
21. Karp C.L., el-Safi S.H., Wynn T.A., Satti M.M., Kordofani A.M., Hashim F.A., Hag-Ali M., Neva F.A., Nutman T.B., Sacks D.L. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-γ J. Clin. Invest. 91:1993;1644-1648
22. Halpern M.D., Kurlander R.J., Pisetsky D.S. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α Cell. Immunol. 167:1996;72-78
23. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ Proc. Natl. Acad. Sci. USA. 93:1996;2879-2883
24. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549
25. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M.D., Silverman G.J., Lotz M., Carson D.A., Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science. 273:1996;352-354
26. Klinman D.M., Barnhart K.M., Conover J. CpG motifs as immune adjuvants. Vaccine. 17:1999;19-25
27. Ballas Z.K., Rasmussen W.L., Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157:1996;1840-1845
28. Cowdery J.S., Chace J.H., Yi A.K., Krieg A.M. Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides. J. Immunol. 156:1996;4570-4575
29. Messina J.P., Gilkeson G.S., Pisetsky D.S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 147:1991;1759-1764
30. Tokunaga T., Yamamoto H., Shimada S., Abe H., Fukuda T., Fujisawa Y., Furutani Y., Yano O., Kataoka T., Sudo T., et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72:1984;955-962
31. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA. 94:1997;10833-10837
32. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1997;1623-1631
33. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M., Weeranta R. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160:1998;870-876
34. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 27:1997;2340-2344
35. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A., Kornbluth R.S., Richman D.D., Carson D.A., Raz E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med. 3:1997;849-854
36. Sun S., Kishimoto H., Sprent J. DNA as an adjuvant: capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J. Exp. Med. 187:1998;1145-1150
37. 8+ T cell responses and protection against Leishmania major infection. J. Exp. Med. 195:2002;1565-1573
38. Zimmermann S., Egeter O., Hausmann S., Lipford G.B., Rocken M., Wagner H., Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J. Immunol. 160:1998;3627-3630
39. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., Vogel J.C. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms. Proc. Natl. Acad. Sci. USA. 96:1999;6970-6975
40. Stacey K.J., Blackwell J.M. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect. Immun. 67:1999;3719-3726
41. Poonam, T., Sukumaran, B., Saxena, S., Madhubala, R. (2004) Immunostimulatory oligodeoxynucleotides are potent enhancers of specific immunity in mice immunized with recombinant ORFF leishmanial antigen vaccine (in press)
42. Dole V.S., Raj V.S., Ghosh A., Madhubala R., Myler P.J., Stuart K.D. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine. 19:2000;423-430
43. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745. Erratum in: Nature 2001. 409:646